DiagnOptics Technologies B.V.

DiagnOptics develops and markets a non-invasive diagnostic technology, which can assess the tissue accumulation of AGEs (Advanced Glycation Endproducts). Since 2006 the AGE Reader provides physicians and researchers with an immediate cardiovascular risk assessment that is essential in diabetes management. DiagnOptics now introduces Diab-spot, a non-invasive test to identify people at risk for diabetes or pre-diabetes without overnight fasting, blood being drawn, or waiting for hours for lab results. Moreover, in a clinical study it was shown that Diab-spot has a better selectivity and specificity than FPG and HbA1c.